*Post updated and made Public August 18th, 2009*
HTDS (Hard To Treat Diseases)
First a little about the Company:
HTDS Medical has found the best way to increase shareholder value, separate and apart from the operating performance of operating subsidiaries, by spinning off and distributing shares of its wholly owned subsidiaries in the form of a special dividend to the Company’s shareholders.
The common stock distributions are part of a broader strategy relating to the transition of HTDS Medical into a company focused on the development and licensing of proprietary technologies.
We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
The company is in the process of merging with a China based medical company. We are also continuing our negotiations with an East European medical company whose primary focus involves the enhancement and modification of existing approved drugs such as “Virazole” for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.
First off, we know you’re thinking….so it’s a company that focuses on stock and its’ shareholders right? Wrong. HTDS, like any company is focused on it’s stock and the inherent value therein, they’re just honest enough to admit it up front. What they really do if you keep reading is to focus on creating new and innovative ways to treat diseases even by improving previous medications. Also this company is unique in the way it goes about its’ goal, it seeks to merge and use the expertise of other already successful companies rather than rely on its’ own resources constantly. Which in our books is a recipe for a successful company.
We have been watching this stock for a few weeks now but we didn’t want to post until we were sure this company was going places, after all Knowledge is power, and we didn’t want to present a stock to any of our faithful readers without the knowledge of where this company is going.
Here’s the secret behind the future success of HTDS. H1N1 vaccine, that’s right a vaccine for Swine Flu, which as we all know to date has no 100% proof vaccine/cure. Although companies are working diligently on developing one currently HTDS has a subsidiary (Mellow Hope) in China that has developed such a vaccine. This is HUGE news! A disease that has the potential for the largest pandemic virus world wide now has a vaccine that is developed, under going tests and is expected to not only have tests finished by September but have a license to distribute by October or November.
Not only is this in itself huge, but the fact that Mellow Hope is the ONLY supplier for the vaccine overseas (specifically China) which means that they have what some could call a monopoly on vaccinating billions of people. Now of course this is great news for stock holders but it’s even better news for the people of China, with such a large population disease has the potential to spread like wildfire.
Here’s a number we want you to consider, the population of China:
1,330,044,544 (as of July 2008)
That’s right over 1 billion people in the country where Mellow Hope will first release this vaccine.
So not only is HTDS helping to develop a vaccine that could guard over 1 billion people (young, old, etc) from getting infected with this previously impervious disease but they are living up to its’ promise of working to create value within its’ stock.
Here’s the news release for the lazy among us:
SHENZHEN, China, Aug. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Mellow Hope,
an operating subsidiary of HTDS, is pleased to report that its clinical trial is currently being processed.
The company expects it will be completed by this September (Approx 60 days). The company expects the manufacturing
license will be released by October or November of this year.
H1N1 (referred to as "swine flu" early on) is a new influenza virus causing illness in people.
This new virus was first detected in people in the United States in April 2009. This virus is spreading from
person-to-person worldwide, probably in much the same way that regular seasonal influenza viruses spread.
On June 11, 2009, the World Health Organization (WHO) signaled that a pandemic of novel H1N1 flu was underway.
Terry Yuan CEO of HTDS said (sic) "With the new H1N1 virus continuing to cause illness,
hospitalizations and deaths in the whole world, it is highly recommended to make preparation for a voluntary
H1N1 vaccination. Mellow Hope is the only one H1N1 vaccine supplier for the overseas market from China."
Link for full story
Additional Notes:
We caught wind of some major investors (aka big boys) pulling out of HTDS recently which knocked the stock price down
a bit, which seems like bad news, but for smaller investors this is great news because it is a prime time to buy into
HTDS. So go ahead,watch the stock if you want, see what it does, but we're predicting nothing but up for this
goldmine of an Uber Stock.
We sent out an email to all the members on our sign up list earlier today when the stock price was at it's
lowest point to give them a perfect opportunity to buy in. But you didn't get that email did you?
That's because you're not signed up, go ahead, sign up,it takes just a minute (literally) of your time.
Invest a minute of your time with us and we'll invest in you.
Remember Knowledge is Money
